Yu P. et al., who compared the plasma level of NCAM1 in 429 coronary heart disease with 93 health controls, proved that the expression level of NCAM1 was significantly associated with cTnT and NT-proBNP, suggesting that NCAM1 may be a therapeutic target of CAD (23). This evidence concerns the gene NPPB and coronary artery disorder.